Article

Allergan to buy Oculex for $230 million in cash

New York-Allergan Inc. will pay nearly $230 million in cash to acquire Oculex Pharmaceuticals Inc., a privately held company specializing in the development of treatments for sight-threatening diseases of the eye.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
© 2025 MJH Life Sciences

All rights reserved.